Stay updated on Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page.

Latest updates to the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page
- Check5 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check20 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference2%
- Check27 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.3%
- Check49 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check63 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed descriptions of a Phase 1b study on poziotinib in combination with T-DM1 for HER2+ breast cancer, and the addition of a new revision number (v2.15.0).SummaryDifference30%
Stay in the know with updates to Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page.